XTAI
3705
Market cap493mUSD
Oct 08, Last price
59.10TWD
1D
2.96%
1Q
8.24%
Jan 2017
29.46%
IPO
43.10%
Name
YungShin Global Holding Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
YungShin Global Holding Corporation, through its various subsidiaries, engages in strategic investments, production, and distribution across a diverse portfolio. Its primary focus lies in the manufacturing and sale of human and veterinary pharmaceuticals, agricultural chemicals, industrial medical products, and cosmetics. The company maintains a significant market presence in Taiwan, Mainland China, Japan, and the United States. Beyond these core areas, YungShin also processes and markets wood products. Its operations include the development and sale of over-the-counter medications, specialized preparations, and chemical intermediates. Furthermore, the corporation offers a range of pharmaceutical services, such as research and development, technology transfer, licensing, and outsourcing, alongside general import and export trading activities. The company's commercial reach extends to the wholesale, retail, and broader trading of health products, beauty items, medical supplies, human testing reagents, and all associated raw materials, semi-finished goods, and manufacturing equipment. Established in 1952, YungShin Global Holding Corporation is headquartered in Taichung, Taiwan.
Key people
Chairman of the Board · since 2023
Chih-Wei Chien
President · since 2023
Ling-Chin Lee
Vice Chairman of the Board · since 2010
Yu-I Lee
Head of Finance & Accounting · since 2020
I-Yun Wang
Corporate Governance Officer
Director · since 2016
Chi Li Lee
Director · since 2019
Director · since 2010
Meng-Be Lin
Director · since 2013
Hong-I Chen
Independent Director · since 2019
Kun-Hsien Lin
Independent Director · since 2016
Independent Director · since 2019
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||